NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept ...

Corcept Therapeutics (CORT) announced the initiation of MOMENTUM, a clinical trial examining the prevalence of endogenous ...

For the year to December 2024, Corcept Therapeutics had an accrual ratio of -0.26. That implies it has very good cash conversion, and that its earnings in the last year actually significantly ...

Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. On average, equities analysts forecast that Corcept Therapeutics will post 1.36 EPS for the current fiscal year.

Is Corcept Therapeutics (CORT) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Corcept Therapeutics is a member of our Medical group ...

Using the 2 Stage Free Cash Flow to Equity, Corcept Therapeutics fair value estimate is US$88.71 Corcept Therapeutics is estimated to be 33% undervalued based on current share price of US$59.85 Our ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Corcept Therapeutics Inc. (CORT) on Wednesday reported fourth-quarter net income of $30.4 million. The Redwood City, California-based ...

Thank you for standing by, and welcome to Corcept Therapeutics conference call. [Operator Instructions] I would now like to hand the call over to Atabak Mokari, CFO. Please go ahead. Hello ...